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Abstract
Background:  Although all patients undergoing total joint arthroplasty are subjected to similar risk
factors that predispose to thromboembolism, only a subset of patients develop this complication.
The objective of this study was to determine whether a specific genetic profile is associated with a
higher risk of developing a postoperative thromboembolic complication. Specifically, we examined
if the Factor V Leiden (FVL) mutation or the deletion polymorphism of the angiotensin-converting
enzyme (ACE) gene increased a patient's risk for postoperative thromboembolic events. The FVL
mutation has been associated with an increased risk of idiopathic thromboembolism and the
d e l e t i o n  p o l y m o r p h i s m  o f  t h e  A C E  g e n e  h a s  b e e n  a s s o c i a t e d  w i t h  i n c r e a s e d  v a s c u l a r  t o n e ,
attenuated fibrinolysis and increased platelet aggregation.
Methods:  The presence of these genetic profiles was determined for 38 patients who had a
postoperative symptomatic pulmonary embolus or proximal deep venous thrombosis and 241
control patients without thrombosis using molecular biological techniques.
Results:  The Factor V Leiden mutation was present in none of the 38 experimental patients and
in 3% or 8 of the 241 controls (p = 0.26). Similarly there was no difference detected in the
distribution of polymorphisms for the ACE gene with the deletion-deletion genotype present in
36% or 13 of the 38 experimental patients and in 31% or 74 of the 241 controls (p = 0.32).
Conclusions:  Our results suggest that neither of these potentially hypercoaguable states are
associated with an increased risk of symptomatic thromboembolic events following total hip or
knee arthroplasty in patients receiving pharmacological thromboprophylaxis.
Background
Patients following total hip and knee arthroplasty are at
a significant risk for thromboembolic complications. De-
spite modern prophylaxis against thromboembolism,
studies still report a 10 to 40% frequency of deep venous
thrombosis and a significant rate of pulmonary embo-
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lism following total hip or knee arthroplasty [1–3]. The
high incidence of thrombotic disease despite prophylaxis
makes early detection imperative, as treatment with an-
ticoagulation is highly effective [4, 5].
Both DVT and PE manifest few specific clinical signs or
symptoms, making the clinical diagnosis neither sensi-
tive nor specific [5–7]. A high index of suspicion based
on risk stratification is necessary for the detection and
appropriate implementation of diagnostic studies to
identify this complication. The ability preoperatively to
identify a subset of patients undergoing adult recon-
structive surgery that are at a higher risk of developing
thromboembolic complications would aid the clinician
in making an accurate diagnosis and make possible fur-
ther research to determine optimal regimes of postoper-
ative detection and prophylaxis.
Until recently, the only known hypercoagulable states
were several rare genetic disorders of the coagulation
cascade (antithrombin III, protein C, and protein S defi-
ciency), which accounted for only a small percentage of
all patients with venous thrombosis [16]. In 1993, Dahl-
back et al. [17] described a previously unreported hyper-
coagulable state among members of three families that
suffered from recurrent venous thrombosis. Further in-
vestigation revealed an autosomal-dominant inherited
defect in the anticoagulant function of factor V resulting
in resistance to the anticoagulant action of activated pro-
tein C (APC) [18]. Formal evidence for this association
came from a large population-based patient-control
study, the Leiden Thrombophilia Study, which followed
474 consecutive patients of less than 70 years of age with
a first episode of objectively confirmed DVT [9]. Twenty-
eight percent of patients in the study group and 5.7% of
controls were found to be APC-resistant. Furthermore, it
was estimated that these patients have a sevenfold great-
er risk of developing a DVT. The abnormal factor V that
causes APC resistance was subsequently termed factor V
Leiden. Later studies confirmed a seven- to-eightfold in-
creased risk for patients heterozygous for the factor V
mutation and an 80-fold increased risk in homozygous
individuals [3,9]. Factor V Leiden is therefore the most
common thrombophilic disorder described, 10 times
more common than all the other genetic coagulopathies
combined, with an estimated prevalence of 5% in the
general population [9, 10, 15].
Although the majority of patients undergoing total hip
and knee arthroplasty are subjected to similar perioper-
ative risk factors that predispose to thromboembolism,
only a subset of patients develop this complication. The
objective of this study was to determine whether the FVL
mutation or the deletion polymorphism of the ACE gene
is associated with a higher risk of developing a postoper-
ative thromboembolic complication.
Patients and Methods
Patients
The presence of the Factor V Leiden mutation and the
deletion-deletion polymorphism of the angiotensin con-
verting enzyme gene were determined for 38 patients
who developed symptomatic pulmonary embolism (30
patients) or proximal deep venous thrombosis (8 pa-
tients) following elective total hip or knee arthroplasty at
our institution between February of 1997 and July of
1999. The prevalence of these genetic profiles was com-
pared to a control cohort of 241 patients who had under-
gone similar procedures between November 1997 and
March of 1998 at the same institution and whose postop-
erative course was not complicated by symptomatic
thromboembolism using an unmatched case-control de-
sign. A total of 321 elective total hip and knee arthro-
plasties were performed during the time period that
samples for the control group were collected, however 14
patients chose not to participate in the study and 7 pa-
tients were discharged to home prior to sample collec-
tion. An additional 59 patients who were clinically
suspected of deep vein thrombosis but had a single neg-
ative duplex ultrasound of the lower-extremities were
also excluded from the analysis.
Pulmonary embolism was diagnosed on the basis of clin-
ical symptoms and signs combined with a high probabil-
ity ventilation-perfusion scan in 20 of the 30, a positive
pulmonary angiogram in 6, a positive high resolution
chest CT in 2 and an intermediate probability ventila-
tion-perfusion scan combined with a high clinical suspi-
cion in 2. The 8 proximal deep venous thrombosis was
diagnosed by duplex ultrasonography in seven and con-
trast venography in 1. Thirty-one of the 38 patients were
treated with intravenous heparin followed by oral warfa-
rin, five by placement of an inferior vena caval and oral
warfarin and two by placement of an inferior vena caval
filter followed by intravenous heparin and oral warfarin
Polymorphisms of the angiotensin converting enzyme
have also been associated with a hypercoaguable state.
The angiotensin converting enzyme (ACE) digests angi-
otensin I to angiotensin II (a potent vasoconstrictor) and
is thus involved with the regulation of vascular tone. The
angiotensin converting enzyme has also been shown to
attenuate fibrinolysis and affect both platelet activation
and aggregation [14]. The ACE gene has been found to
have a polymorphism consisting of an insertion and a de-
letion of a 287 base pair fragment of intron 16 [13]. Pa-
tients may thus be of one of three separate genotypes;
insertion/insertion, deletion/deletion or insertion/dele-
tion. Patients with the deletion/deletion genotype haveBMC Musculoskeletal Disorders (2001) 2:1 http://www.biomedcentral.com/1471-2474/2/1
been shown to have mean plasma ACE levels of approxi-
mately twice that of patients with the insertion/insertion
genotype [13]. Thus patients with the deletion/deletion
genotype may be at increased risk for thromboembolic
events.
Demographic and operative information including rele-
vant past medical history and the type of thromboembol-
ic prophylaxis utilized was collected for the experimental
and control groups as summarized in Table 1. Approval
was obtained from the Institutional Review Board at our
hospital prior to initiating this study and all patients
signed informed consent prior to participating in the
study.
Determination of the Factor V Leiden Mutation
Two-milliliter samples of whole blood were collected in
buffered sodium citrate, and high molecular weight ge-
nomic DNA was obtained from the peripheral blood leu-
kocyte fraction (QIAamp Blood Tissue Kit, Qiagen,
Valencia CA). The factor V Leiden mutation is located in
exon 10, 11 nucleotides 5' of the start of intron 10 at nu-
cleotide 1691, where an adenosine replaces guanidine
[15]. A 169-base-pair DNA fragment of the factor V gene
that includes nucleotide 1691 was amplified utilizing the
polymerase chain reaction (PCR) with the forward prim-
er 5'CATACTACAGTGACGTGGAC3' and the reverse
primer 5'GACCTAACATGTTCTAGCCAGAAG3'. PCR
was performed using a standard protocol as follows with
a final volume of 50 µ l; 5 µ l 10X PCR buffer, 5 µ l 2 mM
dNTP, 5 µ l forward primer (concentration 20 ng/ul), 5 ul
reverse primer (concentration 20 ng/ul), 1.5 µ l 50 mM
MgCl, 0.25 µ l Taq polymerase (5 U/µ l), and 1 µ l sample
purified genomic DNA (concentration approximately 30
ng/µ l) (PCR reagents, Gibco-BRL, Bethesda, MD). Thir-
ty-five cycles of the polymerase chain reaction utilizing a
microprocessor controlled thermal cycler (Perkin-Elm-
er, Norwalk, CT) were then performed to amplify the de-
sired segment utilizing the following parameters; 94° C
for denaturation for 45 seconds, 63° C for 60 seconds for
annealing, and 72° C for 90 seconds for extension.
Table 1: Demographic and Operative Data
Study Group Control Group P Value
N = 38 N = 241
Mean Age (years) 67 63 0.11
Female Sex 33 (87%) 171 (71%) 0.07
Thromboembolic Prophylaxis 0.79
Enoxaparin Sodium 37 (97%) 228 (95%)
Warfarin 1(3%) 13 (6%)
History of Prior Thromboembolism 5(13%) 3 (1%) <0.001
Family History of Thromboembolism 3 (8%) 5 (2%) <0.001
Percent Ideal Body Weight 139% 147% 0.23
History of Smoking 3 (8%) 20 (7%) 0.77
Procedure 0.21
Primary Total Hip Arthroplasty 10(26%) 94 (39%)
Primary Total Knee Arthroplasty 25 (66%) 113 (47%)
Revision Total Hip Arthroplasty 1 (3%) 20 (8%)
Revision Total Knee Arthroplasty 2 (5%) 14 (6%)
Preoperative Diagnosis: Hips 0.71
Osteoarthritis 6 (55%) 75 (66%)
Rheumatoid Arthritis 1 (9%) 4 (4%)
Failed Implant 1 (9%) 20 (18%)
Other 3 (27%) 15 (12%)
Preoperative Diagnosis: Knees 0.8
Osteoarthritis 22 (81%) 101 (79%)
Rheumatoid Arthritis 2 (7%) 7 (6%)
Failed Implant 1 (4%) 14 (11%)
Other 2 (8%) 5 (4%)
Estimated Blood Loss (milliliters) 323 425 0.21
OperativeTime (minutes) 128 145 0.24
Anesthetic 0.09
Neuraxial 30 (78%) 142 (59%)
General 8 (22%) 99 (41%)BMC Musculoskeletal Disorders (2001) 2:1 http://www.biomedcentral.com/1471-2474/2/1
The amplified 169-base-pair fragment was digested with
0.4 U of the restriction enzyme Mnl I (New England Bio
Labs, Beverly, MA) at 37° C for 6-12 hours and the result-
ing fragments were subjected to electrophoresis on 4%
Nu-Sieve GTG agarose gels (FMC Bioproducts, Rock-
land, ME) and the nucleotide bands visualized by ethid-
ium bromide fluorescence and photography. Digestion
yields three fragments (86, 46, and 37 base pairs) in the
normal allele and two fragments (123 and 46 base pairs)
in the mutant allele as the point mutation at position
1691 is associated with loss of the recognition site for Mnl
I. Control digestions were performed with fragments
amplified from cloned DNA with and without the factor
V Leiden mutation.
Determination of Angiotensin Converting Enzyme Poly-
morphisms
The insertion/deletion genotype of subjects was per-
formed using purified genomic DNA (prepared as above)
and the polymerase chain reaction using the forward
primer 5'CTGGAGACCACTCCCATCCTTTCT3' and the
reverse primer 5'GATGTGGCCATCACATTCGTCAGAT3'
as per Rigat et al [13]. PCR was performed using a stand-
ard protocol as follows with a final volume of 50 µ l; 5 µ l
10X PCR buffer, 5 µ l 2 mM dNTP, 5 µ l forward primer
(concentration 20 ng/ul), 5 µ l reverse primer (concen-
tration 20 ng/µ l), 1.5 µ l 50 mM MgCl, 0.25 µ l Taq
polymerase (5 U/µ l), and 1 µ l sample purified genomic
DNA (concentration approximately 30 ng/µ l), and 5 µ l
dimethyl sulfoxide. Thirty-five cycles of the polymerase
chain reaction utilizing a microprocessor controlled
thermal cycler (Perkin-Elmer, Norwalk, CT) were then
performed to amplify the desired segment utilizing the
following parameters; 94° C for denaturation for 60 sec-
onds, 63° C for 90 seconds for annealing, and 72° C for 90
seconds for extension. The PCR products were subjected
to electrophoresis on 1.2% agarose gels and the nucle-
otide bands visualized by ethidium bromide fluorescence
and photography. A 190-bp fragment characterizes the
deletion polymorphism, while the presence of the inser-
tion leads to a 490-bp fragment. Heterozygotes exhibit
an intermediate band that is most likely a heteroduplex
DNA fragment.
Statistical Analysis
Statistical analysis was performed using a two-tailed stu-
dent's t test, Chi square analysis or Mann-Whitney U test
where appropriate with a significance set at p = 0.05. As-
suming an unmatched case control design with alpha =
0.05 and beta = 0.80, post-hoc power analysis was per-
formed to determine the minimum detectable relative
risk detectable with the given sample size [24].
Results
A comparison between the experimental and control
subjects revealed that they were of comparable age and
sex (Table 1I). Operative indications, procedures and
surgical variables were likewise similar in the two groups
of patients (Table 1I). A significant difference was noted
however in that the patients in the experimental group
had a significantly higher percentage of patients with a
personal or family history of thromboembolism (p <
0.001 for both).
The Factor V Leiden mutation was present in none of the
38 experimental patients and in 3% or 8 of the 241 con-
trols (p = 0.26. Odds ratio = 1 with 95% confidence inter-
val 0-3.8). Post-hoc power analysis revealed that with
the number of subjects available, the minimum detecta-
ble risk for the Factor V Leiden mutation being associat-
ed with a higher risk of thromboembolic complications
was 5.9.
Similarly there was no difference detected in the distri-
bution of polymorphisms for the Angiotensin Converting
Enzyme gene with the deletion-deletion genotype
present in 36% or 13 of the 38 experimental patients and
in 31% or 74 of the 241 controls (p = 0.32. Odds ratio =
1.2 with 95% confidence interval 0.5-2.5). Post-hoc pow-
er analysis revealed that with the number of subjects
available, the minimum detectable risk for the deletion-
deletion polymorphism of the ACE gene being associated
with a higher risk of thromboembolic complications was
2.7.
Discussion
Previous authors have examined the relationship be-
tween inherited hypercoagulable states and thromboem-
bolism following total hip and knee arthroplasty with
mixed results. Lowe et al. [19] found that the Factor V
Leiden mutation was associated with an increased risk of
deep venous thrombosis (as determined by routine bilat-
eral ascending venography) in 480 European patients
who had undergone total hip arthroplasty, however only
41 of the 120 patients with deep venous thrombosis had
proximal thrombi. Svensson et al. [20] found that among
a cohort of 100 Swedish patients who had undergone hip
arthroplasty, female patients who were heterozygous for
the factor V Leiden mutation had a four-fold increased
risk of thrombosis. The authors felt, however, that based
on their data, no definite association between the Factor
V Leiden mutation and postoperative thrombosis could
be made. In contrast, Ryan et al. [21] studied 825 pa-
tients who had routine bilateral ascending venography
following total hip and knee arthroplasty and found that
the prevalence of the Factor V Leiden mutation was no
different between patients who did and did not have
venographic evidence of deep venous thrombosis. Simi-BMC Musculoskeletal Disorders (2001) 2:1 http://www.biomedcentral.com/1471-2474/2/1
larly, Woolson et al. [22] studied 36 patients who had a
proximal deep venous thrombosis after total hip arthro-
plasty (detected by routine predischarge compression
duplex ultrasound) and found that the prevalence of the
Factor V Leiden was no different in that population com-
pared to 45 controls. In contrast to the aforementioned
studies, the present report studied patients who had de-
veloped symptomatic thromboembolic events (the ma-
jority of which were pulmonary embolism) and were all
treated with a uniform thromboembolic prophylaxis re-
gime. Our results support the findings of others, that in
patients receiving pharmacological prophylaxis against
postoperative thrombosis, the Factor V Leiden mutation
is not associated with an increased risk of symptomatic
thromboembolism following total hip or knee arthro-
plasty.
While Phillip et al. [23] found no association between the
Factor V Leiden mutation and deep venous thrombosis,
they did find that the deletion-deletion genotype of the
angiotensin converting enzyme was strongly associated
with postoperative venous thrombosis in 85 patients
who had undergone total hip arthroplasty (30 of whom
had a thromboembolic event as detected by routine com-
pression duplex ultrasound). They concluded that pa-
tients with the deletion/deletion genotype were at a 10-
fold increased risk for a thromboembolic event following
total hip arthroplasty as compared to patients with the
insertion-insertion genotype. However, 12 of the 30 ex-
perimental subjects had isolated distal deep venous
thrombosis (which is of questionable clinical signifi-
cance) and only 10% had a pulmonary embolism. While
the results of this study had encouraged us to screen our
patient population for these polymorphisms, when uti-
lizing a more relevant clinical endpoint (symptomatic
pulmonary embolism or deep venous thrombosis) we
were unable to confirm this association.
Due to the relative infrequence of symptomatic throm-
boembolic events while using pharmacological agents as
prophylaxis, an unmatched case-control study design
was employed. This type of study design has the advan-
tage of increased statistical power for studying relatively
rare events [24]. However, its disadvantages include the
possibility that other variables that were not controlled
for could have affected our results. The patients in both
the case and control groups were operated on during
overlapping time periods and were found to be demo-
graphically similar, and thus we do not believe that such
confounding variables affected our results. Our power
analysis reveals that a relatively strong association be-
tween these genetic profiles and postoperative throm-
boembolism (5.9 fold increased risk for the factor V
Leiden mutation and a 2.7 fold increased risk for the de-
letion/deletion polymorphism of the angiotensin con-
verting enzyme gene) would have been required to detect
a significant difference between the prevalence of these
mutations in our case and control groups. Likewise, a
larger number of patients would have been required to
find a significant difference if a weaker association was
assumed. However, no trend was detected in our data to
suggest that such an association was present. Further-
more, such a weak association would make preoperative
screening and identification of such patients not cost ef-
fective.
It was noted however, that a significantly greater per-
centage of patients who suffered a thromboembolic
event had a personal or family history of thromboembo-
lism (p = 0.001 for both). The report by Woolson et al.
[22] included similar findings. Although residual abnor-
malities of the deep venous system could account for the
higher prevalence of a personal history of prior deep ve-
nous thrombosis or pulmonary embolism, the higher
prevalence of a family history of thromboembolic events
suggests that an as yet undescribed genetically deter-
mined hypercoagulable state or predisposition may be
present in these patients.
Conclusions
The objective of this study was to determine whether a
specific genetic profile is associated with a higher risk of
developing a postoperative thromboembolic complica-
tion. Although our results suggest that neither of these
potentially hypercoaguable states are associated with an
increased risk of symptomatic thromboembolic events
following total hip or knee arthroplasty in patients re-
ceiving pharmacological thromboprophylaxis, an as yet
undescribed genetically determined hypercoagulable
state or predisposition may be present in these patients.
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